Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2016, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline landscape.
Gastroesophageal (GE) junction adenocarcinomas are carcinomas of the esophagus and the gastro-esophageal junction. Symptoms include dysphasia, weight loss, cough, odynophagia, pain and hoarseness. Risk factors include age, overweight or obese, gastroesophageal reflux disease (GERD), smoking and alcoholism. Treatment includes chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 23, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.Adenocarcinoma Of The Gastroesophageal Junction.
Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
- The pipeline guide reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Adenocarcinoma Of The Gastroesophageal Junction Overview 8
Therapeutics Development 9
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview 9
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis 10
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies 11
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes 13
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies 17
Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes 20
Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development 21
AB Science SA 21
AbbVie Inc 22
Advenchen Laboratories, LLC 23
Amgen Inc. 24
ArQule, Inc. 25
AstraZeneca Plc 26
Boehringer Ingelheim GmbH 27
Boston Biomedical, Inc. 28
Bristol-Myers Squibb Company 29
Cerulean Pharma, Inc. 30
Daiichi Sankyo Company, Limited 31
Dr. Reddy's Laboratories Limited 32
Eli Lilly and Company 33
F. Hoffmann-La Roche Ltd. 34
Ganymed Pharmaceuticals AG 35
Genentech Inc 36
Gilead Sciences, Inc. 37
Hutchison MediPharma Limited 38
Imugene Limited 39
Mebiopharm Co., Ltd. 40
MedImmune LLC 41
Merck & Co., Inc. 42
Merck KGaA 43
Millennium Pharmaceuticals Inc 44
Neopharm Ltd. 45
Novartis AG 46
Oncobiologics, Inc. 47
Panacea Biotec Limited 48
Sanofi 49
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
AL-3818 - Drug Profile 62
alpelisib - Drug Profile 64
AMG-337 - Drug Profile 67
atezolizumab - Drug Profile 69
avelumab - Drug Profile 83
AZD-4547 - Drug Profile 94
AZD-6738 - Drug Profile 96
BI-853520 - Drug Profile 97
cabazitaxel - Drug Profile 98
catumaxomab - Drug Profile 100
Cellular Immunotherapy for Oncology - Drug Profile 102
ceritinib - Drug Profile 103
CRLX-101 - Drug Profile 108
DS-8201 - Drug Profile 119
durvalumab - Drug Profile 120
durvalumab + tremelimumab - Drug Profile 131
emibetuzumab - Drug Profile 135
GS-5745 - Drug Profile 137
ibrutinib - Drug Profile 139
IMAB-362 - Drug Profile 165
IMU-131 - Drug Profile 167
ipatasertib - Drug Profile 171
ipilimumab - Drug Profile 173
JS-001 - Drug Profile 182
LAG-525 - Drug Profile 183
LY-3127804 - Drug Profile 184
masitinib - Drug Profile 185
merestinib - Drug Profile 199
napabucasin - Drug Profile 201
nimotuzumab - Drug Profile 208
oxaliplatin - Drug Profile 212
panitumumab - Drug Profile 214
PDR-001 - Drug Profile 219
pembrolizumab - Drug Profile 221
pertuzumab - Drug Profile 258
ramucirumab - Drug Profile 264
SAR-408701 - Drug Profile 274
savolitinib - Drug Profile 275
serabelisib - Drug Profile 279
sonidegib phosphate - Drug Profile 281
tivantinib - Drug Profile 285
trastuzumab biosimilar - Drug Profile 291
trastuzumab biosimilar - Drug Profile 293
trastuzumab biosimilar - Drug Profile 294
trastuzumab biosimilar - Drug Profile 295
trastuzumab biosimilar - Drug Profile 296
tremelimumab - Drug Profile 297
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects 300
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products 302
Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones 303
Featured News & Press Releases 303
Appendix 316
Methodology 316
Coverage 316
Secondary Research 316
Primary Research 316
Expert Panel Validation 316
Contact Us 316
Disclaimer 317
List Of Tables
List of Tables
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016 12
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Development by Companies, H2 2016 (Contd..2) 22
Products under Investigation by Universities/Institutes, H2 2016 23
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2016 24
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc, H2 2016 25
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H2 2016 26
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2016 27
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2016 28
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2016 29
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2016 30
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2016 31
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2016 32
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2016 33
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 35
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2016 36
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2016 38
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech Inc, H2 2016 39
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2016 40
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H2 2016 41
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2016 42
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2016 43
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune LLC, H2 2016 44
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2016 45
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2016 46
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 47
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Neopharm Ltd., H2 2016 48
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2016 49
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H2 2016 50
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2016 51
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2016 52
Assessment by Monotherapy Products, H2 2016 53
Assessment by Combination Products, H2 2016 54
Number of Products by Stage and Target, H2 2016 56
Number of Products by Stage and Mechanism of Action, H2 2016 59
Number of Products by Stage and Route of Administration, H2 2016 62
Number of Products by Stage and Molecule Type, H2 2016 64
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2016 303
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd..1), H2 2016 304
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2016 305
List Of Figures
List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016 12
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 18
Assessment by Monotherapy Products, H2 2016 53
Number of Products by Top 10 Targets, H2 2016 55
Number of Products by Stage and Top 10 Targets, H2 2016 55
Number of Products by Top 10 Mechanism of Actions, H2 2016 58
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 58
Number of Products by Routes of Administration, H2 2016 61
Number of Products by Stage and Routes of Administration, H2 2016 61
Number of Products by Molecule Types, H2 2016 63
Number of Products by Stage and Molecule Types, H2 2016 63
